PAW Hepatoadvanced is a convenient, chewable tablet containing a blend of bioavailable antioxidants, providing detoxification support in the management of canine and feline liver disease via the following means:

• Supports the production of glutathione
• Promotes liver detoxification
• May protect against negative effects on the liver caused by some medications
• Supports liver health in pets presenting with acute liver toxicity
• Supports brain health in dogs

Active Ingredients:

• (S) S-Adenosyl methionine disulfate tosylate (Equivalent to S- SAMe) 100 mg
• D-alpha tocopherol acetate (vitamin E) 60 IU
• Silybin/ phospholipids Equivalent to silybin phosphatidylcholine (Equivalent to silybin A+B) 26 mg

Dose:

• Cat/Dog Weight Dosage
  1-2.4 kg 1 tablet
  2.5-9.9 kg 2 tablets
  10-14.9 kg 3 tablets

For optimal absorption, administer Hepatoadvanced (as per the dosing chart above), once a day on an empty stomach. The recommended total daily dose for dogs and cats is SAMe 10- 20mg/kg, SPC 2.7- 5.4mg/kg and vitamin E 10-15IU/kg. Hepatoadvanced can be used concomitantly with other common hepatic supportive treatments, such as prescription diets, ursodeoxycholic acid, anti-inflammatories, and other non- vitamin E containing nutritional supplements. Regular re-assessment (e.g. every 1-3 months) is recommended to ensure the optimal dose is achieved to reach the desired therapeutic outcome.

Features and Benefits:

• Simple and convenient dosing in the form of a tasty chewable tablet
• Formulated with delayed release technology, enabling steady metabolism by the liver and a prolonged duration of activity
• Contains a unique and stable form of S-adenosylmethionine (SAMe), a precursor to the potent antioxidant glutathione, which is hepatoprotective.
• Contains silybin in a phospholipid complex, which has been shown to provide significantly enhanced bioavailability in dogs and cats compared to standardised milk thistle
• Contains vitamin E in its formulation, preventing the need for additional supplementation

Hepatoadvanced may be used as an adjunctive therapy in conditions such as:

• Chronic hepatitis

• Hepatic lipidosis

• Cholangiohepatitis

• Paracetamol toxicity

• Hepatotoxic mushroom ingestion

• Copper related hepatopathy

• Iron overload

• Medication use including NSAIDs, phenobarbital and corticosteroids (note: does not prevent corticosteroid-induced hepatic vacuolar change)

• Metabolic hepatopathies

• Other acute or chronic hepatopathies

• Neoplasia

• Canine cognitive dysfunction

• Cirrhosis